SuperworthAligos Therapeutics ALGS
- Market cap
- n/a
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $3.7M
- +19% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- n/m
- not a meaningful number
Aligos Therapeutics' trailing earnings are negative, so it has no PE. Revenue was $3.7M over the last twelve months, up 19% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.1M | $672K | $694K+396% | $1.1M−75% | $1.3M+15% | $606K−10% | $311K−55% | $965K−9% | $741K−41% | $169K−72% | $2.8M+810% | $0 | |
| R&D | $15.9M−11% | $22.3M+17% | $16.4M−10% | $21.1M+26% | $16.8M+6% | $16M−28% | $14.5M−11% | $14M−34% | $23.9M+43% | $17M+6% | $23.4M+61% | $24.1M+72% |
| SG&A | $6.4M+22% | $6.4M−10% | $6.7M−22% | $6.4M−31% | $4.6M−28% | $5.2M−20% | $5.1M−24% | $5.6M−13% | $5.2M+12% | $4.9M−4% | $6.4M+27% | $5.6M+1% |
| −$19.1M+1% | −$26M+15% | −$22M−8% | −$26.4M+38% | −$20.1M+6% | −$20.6M−21% | −$19.2M−13% | −$18.6M−30% | −$28.4M+41% | −$21.8M+6% | −$26.9M+40% | −$1.9M−90% | |
| Pre-tax income | −$18M−4% | −$27.9M+28% | −$34.8M+52% | $5.3M | −$19.2M+6% | −$82.1M+194% | $43.1M | −$15.7M | −$31.5M+64% | −$19.9M−76% | −$22.7M | $1.3M |
| $29K | −$30K | $24K−39% | $189K−75% | $91K+214% | $27K | $43K+79% | $185K−2% | $56K−39% | $30K+11% | $317K+637% | $2.8M+1420% | |
| Net income | −$18M−3% | −$27.9M+27% | −$34.9M+52% | $5.1M | −$19.3M+7% | −$82.2M+195% | $43.1M | −$15.9M | −$31.5M+64% | −$19.9M−76% | −$23M | −$1.5M−91% |
| −$10.37−6% | −$5.53−57% | −$5.58−58% | $0.81 | −$3.07−70% | −$13.08+137% | −$2.11−62% | −$1.53 | −$3.04−1% | −$1.91−85% | −$2.21+5% | −$0.14−91% | |
| 1.7M+2% | 5M+194% | 6.2M+264% | 6.3M+263% | 6.3M+261% | 6.3M+25% | 8.7M+39% | 10.4M+65% | 10.4M+65% | 10.4M+65% | 10.4M+19% | 10.4M+1% |
Income tax: Q1 FY20: 6 months less the 3 months printed beside them.
EPS, diluted: 6 periods, Q4 FY19 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 6 periods, Q4 FY19 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
More on Aligos Therapeutics
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .